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Edited by Berend WieringaAbstract Glycogen synthase kinase (GSK) 3b is a multifunc-
tional protein that positively regulates myocardial apoptosis
and negatively regulates hypertrophy. However, the role of
GSK3b in the diabetic myocardium is largely unknown. We
found that GSK3b became more active (less phosphorylated at
serine 9) via decreased Akt phosphorylation, in parallel to c-
Jun NH2 terminal kinase activation, which correlated with in-
creased activated caspase 3 and myocardial apoptosis 3 days
after streptozotocin (STZ) injection in mice. However, 28 days
after STZ injection, GSK3b became inactive, which correlated
with the enhanced protein kinase C b2 and p38 mitogen activated
protein kinase expression, nuclear translocation of nuclear factor
of activated T cells c3, cardiac hypertrophy and ﬁbrosis. All of
the above parameters were exacerbated in dominant-negative
14-3-3 transgenic mice. Our results suggest that GSK3b together
with 14-3-3 protein plays essential roles in the signaling of
diabetic cardiomyopathy, and treatment with either losartan or
tempol prevents these changes.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hypertrophy1. Introduction
Glycogen synthase kinase (GSK) 3b is a multifunctional
protein, and is normally active in cells [1]. However, its in-
creased activation has been shown to induce myocardial apop-
tosis [2]. Protein kinase B also called Akt, phosphorylates
GSK3b at serine 9, and GSK3b thereby becomes inactive,Abbreviations: ANP, natriuretic peptide; AT1, angiotensin II type 1;
BW, body weight; DN, dominant negative; GSK, glycogen synthase
kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HW,
heart weight; HW/BW, the ratio of HW to BW; JNK, c-Jun NH2
terminal kinase; MAPK, mitogen activated protein kinase; NFAT,
nuclear factor of activated T cells; NTG, non-transgenic; PKC, protein
kinase C; S.E.M., standard error mean; STZ, streptozotocin; TBS,
Tris-buﬀered saline; TGF, transforming growth factor; TG, transgenic
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doi:10.1016/j.febslet.2006.02.056which leads to cardiac hypertrophy [3]. Recently, it has been
demonstrated that inhibition of 14-3-3 protein causes increased
phosphorylation of serine 9 and inactivation of GSK3b [4].
Diabetic cardiomyopathy is associated with cardiac apoptosis,
hypertrophy and ﬁbrosis [5,6]. However, the role of GSK3b in
diabetic cardiomyopathy is largely unknown. The present
study is sought to examine whether GSK3b plays a role in
mediating cardiac apoptosis and hypertrophy in the diabetic
myocardium. The relationship between GSK3b and 14-3-3
protein in the diabetic myocardium was further examined by
using transgenic (TG) mice with cardiac-speciﬁc overexpres-
sion of a dominant-negative (DN) mutant of 14-3-3 protein.
Diabetic myocardium is associated with the increased levels
of angiotensin II and oxidative stress [7–9]. Current treatments
for diabetes-associated cardiomyopathy consist of b-blockers,
thiazolidinediones and angiotensin II converting enzyme inhib-
itors [10]. Clinically, the eﬀect of angiotensin II type 1 (AT1)
receptor blockers in diabetic cardiomyopathy are not well
understood. Recent studies have demonstrated that treatment
with antioxidants inhibits hypertrophic responses of cardiac
myocytes [11]. The present study examined the eﬀects of treat-
ment with losartan, an AT1 receptor blocker, and tempol, a
superoxide dismutase mimetic, and attempted to clarify their
molecular signaling mechanisms in mediating diabetes-induced
myocardial apoptosis, hypertrophy and ﬁbrosis.
The results of our study show thatGSK3b together with 14-3-
3 protein regulates the signaling in diabetes-induced myocardial
apoptosis, hypertrophy and ﬁbrosis. Also, treatment with either
losartan or tempol signiﬁcantly attenuated diabetes-induced
myocardial apoptosis, hypertrophy and ﬁbrosis through
improving GSK3b-mediated signaling and associated events.2. Materials and methods
2.1. Materials
Losartan was kindly donated by Banyu Pharmaceuticals, Tokyo, Ja-
pan. Tempol was purchased from Wako Chemicals, Osaka, Japan.
Streptozotocin (STZ) was purchased from Sigma–Aldrich Inc., St.
Louis, MO, USA. Polyclonal angiotensin II antibody was obtained
from Peninsula Laboratories Inc., San Carlos, CA, USA. Monoclonal
phospho-Akt (Ser 473), polyclonal Akt, polyclonal phospho GSK3b
(Ser 9), polyclonal GSK3b, polyclonal cleaved caspase 3, polyclonal
phospho-p38 mitogen activated protein kinase (MAPK) (Thr 180/
Tyr 182), polyclonal p38 MAPK, polyclonal phospho-c-Jun NH2 ter-
minal kinase (JNK), and polyclonal JNK antibodies were obtainedblished by Elsevier B.V. All rights reserved.
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AT1 receptor, polyclonal p22 phox, polyclonal nuclear factor of acti-
vated T cells (NFAT) c3, polyclonal atrial natriuretic peptide (ANP),
polyclonal transforming growth factor (TGF) b1, polyclonal collagen
III, polyclonal protein kinase C (PKC) b2 and polyclonal glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) antibodies were obtained
from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA.
2.2. Generation of DN-14-3-3 TG mice
DN-14-3-3 TG mice were generated as described previously [12]. In
brief, the coding region of the human DN (R56A and R60A) 14-3-3g
cDNA with a 5 0-Myc-1 epitope tag was subcloned into a vector
containing the a-myosin heavy chain promoter and an SV40 polyade-
nylation site. Linearized DNA was injected into the pronuclei of one-
cell C57BL/6 XSJL embryos at the Neuroscience Transgenic Facility at
Washington University School of Medicine. Progeny were backcrossed
into the C57BL/6 genetic background and were analyzed by polymer-
ase chain reaction to detect transgene integration using mouse-tail
DNA as template. Age-matched C57BL/6 JAX mice (obtained from
Charles River Japan Inc., Kanagawa, Japan) were used as non-
transgenic (NTG) controls.
2.3. Diabetes induction
STZ was administered by a single intraperitoneal injection at the
dose of 150 mg/kg body weight (BW) to 8–10-week-old male DN-14-
3-3 and NTG mice. STZ was dissolved in 20 mM sodium citrate saline
buﬀer (pH 4.5) and injected within 5 min of preparation. Age-matched
DN-14-3-3 and NTG mice were injected with 100 ll of citrate buﬀer
and used as non-diabetic controls. Mice were maintained with free ac-
cess to water and chow throughout the period of study, and the ani-
mals were treated in accordance with the guidelines for animal
experimentation of our institute.
2.4. Experimental protocol
Animals were studied at two times after streptozotocin administra-
tion, i.e., on day-3 for acute study and on day-28 for chronic study.
For each of these examinations times, both TG and NTG mice were
divided into the following 6 groups: (1) vehicle-treated normal (non-
STZ-induced) group (N), (2) STZ-induced and vehicle-treated group
(D), (3) STZ-induced and losartan-treated group (D + L), (4) STZ-in-
duced tempol-treated group (D + T), (5) Losartan-treated normal
group, and (6) Tempol-treated normal group. For the 3-day time-per-
iod study, treatment with either losartan or tempol was started from 3
days before the administration of STZ, and continued up to 3 days
after STZ injection. Losartan (60 mg/kg/day) was dissolved in water
and given orally once a day, while tempol (1.5 mmol/kg/day) was dis-
solved in normal saline and administered intraperitoneally once a day.
For the 28-day time-period study, either losartan or tempol was started
from 24 h before the administration of STZ, and continued for 28 days
after STZ injection. Losartan (12 mg/kg/day) and tempol (1 mmol/L)
were dissolved in drinking water and given ad labium. Drug dosage
and solvents for drugs were adopted from Refs. [13,14].
BWs and blood glucose levels of animals were measured before and
at the end of each time-period protocol. Animals’ blood glucose levels
were determined using Medi-safe chips (Terumo Inc., Tokyo, Japan).
At the end of each protocol, mice were anesthetized with a single intra-
peritoneal injection of pentobarbital (50 mg/kg), and the hearts were
excised. Heart weight (HW) and the ratio of HW to BW (HW/BW)
were determined for each animal. The left ventricle was quickly dis-
sected and cut into two parts. One part was immediately transferred
into liquid nitrogen and then stored at 80 C for protein analysis.
The other part was either stored in 10% formalin to make paraﬃn sec-
tions or stored at 80 C after the addition of Tissue-Tek OCT com-
pound (Sakura Co. Ltd., Tokyo, Japan) to make frozen tissue sections.
2.5. Immuno-histochemistry for angiotensin II and NFATc3
Frozen cardiac tissue sections were ﬁxed in acetone, and the slides
were washed in Tris-buﬀered saline (TBS; 10 mmol/L Tris–HCl,
0.85% NaCl, pH 7.5) containing 0.1% BSA. Endogenous peroxidase
activity was quenched by incubating the slides in methanol and 0.6%
H2O2 in methanol. Blocking was done with normal serum. After over-
night incubation with either anti-angiotensin II antibody (1:50 dilution)
or anti-NFATc3 antibody (1:25 dilution) at 4 C, the slides werewashed in TBS buﬀer and HRP conjugated secondary antibody (Santa
Cruz) was added and incubated at room temperature for 45 min. The
immuno-staining was visualized using diamino benzidine tetrahydro-
chloride the slides were counterstained with hematoxylin. A negative
control without primary antibody was included in the experiment to en-
sure the antibody speciﬁcity. Brown colored immuno-positive angioten-
sin II spots were counted at 1000· magniﬁcation, and depicted as the
average number of immuno-positive myocytes per ﬁeld. Nuclear trans-
location of NFATc3 was measured by counting the average number of
nuclei stained with anti-NFATc3 antibody per high power ﬁeld
(1000·). For both cases, 50 random ﬁelds representing the whole sec-
tion were examined per section, and 3 animals were used per group.
2.6. Protein analysis by Western blotting
Protein lysate was prepared from heart tissue as described previously
[15]. The total protein concentration in samples was measured by a
modiﬁed Lowry method. For Western blotting experiments, 100 lg
of total protein was loaded and proteins were separated by SDS–
PAGE (200 V for about 40 min) and electrophoretically transferred
to nitrocellulose ﬁlters (semi-dry transfer at 10 V for 30 min). Filters
were blocked with 5% non-fat dry milk in TBS-T (20 mM Tris, pH
7.6, 137 mM NaCl and 0.1% Tween 20). All antibodies were used at
a dilution of 1:1000. After incubation with primary antibody, bound
antibody was visualized with horseradish peroxidase-coupled second-
ary antibody (Santa Cruz), and chemiluminescence developing agents
(ECL Plus, Amersham). The expression of phospho-Akt, phospho-
GSK3b, phospho-p38 MAPK and phospho-JNK was normalized by
the basal level of Akt, GSK3b, p38 MAPK and JNK, respectively.
The level of expression of AT1 receptor, p22 phox, activated caspase,
ANP, TGFb1, collagen III and PKCb2 was normalized by GAPDH
protein expression in the same sample. The level of expression of each
protein in normal NTGmice was taken as one arbitrary unit. For Wes-
tern blotting analysis, all primary antibodies were used at a dilution of
1:1000 and secondary antibodies were used at a dilution of 1:5000.
2.7. TUNEL apoptosis analysis
Frozen left ventricular (LV) tissues embedded in OCT compound
were cut into 4-lM thick sections and ﬁxed in 4% paraformaldehyde
(pH 7.4) at room temperature. TUNEL analysis was performed as
speciﬁed in the in situ apoptosis detection kit (Takara Bio Inc., Shiga,
Japan). Sections were mounted and examined using light microscopy.
For each animal, ﬁve sections were scored for apoptotic nuclei. Only
nuclei that were clearly located in cardiac myocytes were scored.
2.8. Myocardial cell size measurement
Paraﬃn-embedded LV tissue sections stained with hematoxylin-
eosin, were used for measuring cell size. The short axis diameter of car-
diac myocytes was measured for 10 myocytes selected per ﬁeld (about
50 ﬁelds were selected per section) at 400-fold magniﬁcation by light
microscopy. Each average value was obtained based on the data from
10 myocytes and was used as an independent sampling value.
2.9. Measurement of myocardial ﬁbrosis
The area of myocardial ﬁbrosis in LV tissue sections stained with
Azan-Mallory was quantiﬁed using a color image analyzer (CIA-102,
Olympus, Tokyo, Japan), based on the diﬀerence in color (blue ﬁbrotic
area as opposed to red myocardium) [16].
2.10. Statistical analysis
Data are presented as means ± standard error mean (S.E.M.). Statis-
tical analysis of diﬀerences between groups was performed by one-way
analysis of variance followed by Tukey’s method using JSTAT soft-
ware. Diﬀerences were considered signiﬁcant at P < 0.05.3. Results
3.1. Eﬀect of treatment with losartan or tempol on blood glucose,
BW, HW and HW/BW
Treatment of STZ-induced diabetic mice with losartan or
tempol did not alter the hyperglycemic state of the animals in
Table 1
Changes in blood sugar level, body and heart weights and HW/BW in mice with or without the treatment of either losartan or tempol for 28 days
NTG TG
N D D + L D + T N D D + L D + T
Blood sugar level (mg/dl) 155 ± 28 489 ± 31** 531 ± 18** 528 ± 21** 157 ± 25 501 ± 12## 497 ± 19## 512 ± 19##
Body weight (g) 23.8 ± 0.98 20.1 ± 0.48* 22.1 ± 0.41 21.1 ± 0.21 25.4 ± 0.64 22.2 ± 0.48# 23.8 ± 0.61 22.9 ± 0.39
Heart weight (mg) 102 ± 4.1 93 ± 5.2* 96 ± 4.7 96 ± 4.1 105 ± 6.5 97 ± 5.1# 101 ± 5.5 98 ± 4.5
HW/BW (mg/g) 4.31 ± 0.32 4.36 ± 0.59 4.34 ± 0.52 4.33 ± 0.47 4.14 ± 0.46 4.31 ± 0.51# 4.25 ± 0.43 4.24 ± 0.44
Values are means ± S.E.M. HW/BW, the ratio of heart weight to body weight; N, normal (non-STZ-induced, age matched); D, STZ-induced
diabetic; D + L, STZ-induced diabetic, treated with losartan; D + T, STZ-induced diabetic treated with tempol (for drug treatment protocol, see
Section 2). *P < 0.05, **P < 0.01 vs. N of NTG mice; #P < 0.05, ##P < 0.01 vs. N of TG mice. The results are means ± S.E.M. from 6 animals per
group.
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levels remained elevated in the losartan-treated and tempol-
treated groups. The BW, HW and HW/BW parameters were
not signiﬁcantly changed in normal animals (non-STZ induced)
treated with losartan or tempol compared to those in normal
animals (no drug treatment). Therefore, the BW, HW and
HW/BW data of normal animals treated with losartan and tem-
pol are not shown. STZ administration elevated the blood glu-
cose level 3 days after STZ injection, and treatment period of
STZ-induced diabetic mice with either losartan or tempol for
3-days did not show any signiﬁcant changes in BW, HW or
HW/BW compared to those in normal (non-STZ administered)
and STZ-administered animals, so these data are not shown.
Treatment with either losartan or tempol for a 28-day time per-
iod slightly improved the BW and HW (Table 1). HW/BW was
signiﬁcantly increased 28 days after STZ injection in the TG
group relative to the age-matched normal animals, and the
HW/BW was improved after treatment with either tempol or
losartan, while the HW/BW did not diﬀer signiﬁcantly among
NTG groups (Table 1). Animals which had blood glucose level
higher than 300 mg/dl were used for further experiments. The
results are means ± S.E.M. from 6 animals per group.
3.2. STZ injection induces myocardial angiotensin II and
oxidative stress
The number of angiotensin II-positive cardiac myocytes was
elevated in both TG and NTGmice 3 days (Fig. 1A and B) and
28 days (Fig. 1C) after STZ injection relative to that in age-
matched normal animals. Furthermore, the expression of
AT1 receptor was signiﬁcantly upregulated in both TG and
NTG mice 3 days (Fig. 1D and F) and 28 days (Fig. 1E and
H) after STZ injection. However, the number of angiotensin-
II positive cardiac myocytes and the expression of AT1 recep-
tor did not diﬀer signiﬁcantly between TG and NTG mice 3
and 28 days after STZ injection. Treatment with either losar-
tan or tempol signiﬁcantly attenuated the expression of myo-
cardial angiotensin II and AT1 receptor 3 days and 28 days
after STZ injection (Fig. 1A–H).
Myocardial expression of p22 phox, a component of
NADPH oxidase, was elevated in both TG and NTG mice 3
days (Fig. 1D and G) and 28 days (Fig. 1E and I) after STZ
injection. However, the expression of p22 phox was signiﬁ-
cantly higher in TG mice than in NTG mice on both day 3
(Fig. 1D and G) and 28 (Fig. 1E and I) after STZ injection.
The results are means ± S.E.M. from 3–5 experiments.
3.3. GSK3b signaling in STZ-induced myocardial apoptosis
The phosphorylation of Akt and GSK3b was signiﬁcantly
decreased in the myocardium of both TG and NTG mice 3days after STZ injection relative to that in age-matched normal
animals (Fig. 2A–C). These results are in accord with the in-
creased expression of activated caspase 3 (Fig. 2A and D)
and increased myocardial apoptosis (Fig. 2E and F) 3 days
after STZ injection in both TG and NTG mice. However, a
signiﬁcant decrease in the phosphorylation of Akt and GSK3b,
but an increase in the expression of activated caspase 3 and in
myocardial apoptosis were found in TG mice relative to NTG
mice 3 days after STZ injection (Fig. 2A–F). Treatment with
either losartan or tempol signiﬁcantly improved the phosphor-
ylation status of Akt and GSK3b, and attenuated the expres-
sion of activated caspase and myocardial apoptosis in both
TG and NTG mice 3 days after STZ injection (Fig. 2A–F).
The results are means ± S.E.M. from 3–5 experiments. Myo-
cardial apoptosis and the expression of activated caspase were
did not diﬀer signiﬁcantly before and 28 days after STZ injec-
tion (data not shown).
3.4. GSK3b phosphorylation and NFATc3 nuclear translocation
The phosphorylation of Akt did not diﬀer signiﬁcantly
among groups 28 days after STZ injection (Fig. 3A and C).
However, the phosphorylation of GSK3b was slightly elevated
in NTG mice but signiﬁcantly elevated in TG mice 28 days
after STZ injection relative to that in the age-matched normal
animals (Fig. 3A and D). The increased phosphorylation of
GSK3b was accompanied by increased expression of PKCb2
28 days after STZ injection (Fig. 3A and B). These results
are in accord with the nuclear translocation of NFATc3, a
transcription factor involved in cardiac hypertrophy [17].
While NFATc3-positive nuclei were signiﬁcantly elevated 28
days after STZ injection in both TG and NTG mice (Fig. 3E
and F), the average number of nuclei stained with anti-
NFATc3 antibody was signiﬁcantly higher in TG mice relative
to NTG mice 28 days after STZ injection (Fig. 3E and F).
Treatment with either losartan or tempol signiﬁcantly attenu-
ated the expression of PKCb2, the phosphorylation of GSK3b
and the nuclear translocation of NFATc3 in both TG and
NTG mice 28 days after STZ injection (Fig. 3A–F). The results
are means ± S.E.M. from 3–5 experiments.
3.5. Treatment with losartan or tempol attenuates diabetes-
induced myocardial hypertrophy and ﬁbrosis
The average cross-sectional diameter of cardiac myocytes
was slightly increased in NTG mice, but signiﬁcantly increased
in TG mice 28 days after STZ injection (Fig. 4A and C). At the
same time, the % of myocardial ﬁbrosis was signiﬁcantly ele-
vated in both TG and NTG mice 28 days after STZ injection
(Fig. 4B and D). The expression of molecular markers of car-
diac hypertrophy (ANP) and ﬁbrosis (TGFb1 and collagen III)
Fig. 1. Streptozotocin (STZ) injection elevates myocardial angiotensin II and oxidative stress. (A) Myocardial tissue sections performed with
immuno-histochemical staining for angiotensin II, three days after STZ injection. NTG, non-transgenic; TG, transgenic. N, Normal (non-STZ-
induced, age matched); D, STZ-induced diabetic; D + L, STZ-induced diabetic, treated with losartan; D + T, STZ-induced diabetic treated with
tempol (for drug treatment protocol, see Section 2). Arrows indicate myocyte stained with angiotensin II. Magniﬁcation 1000·. (B, C) Quantiﬁcation
of angiotensin II positive myocytes per high power ﬁeld at 1000· magniﬁcation on 3 days (B) and 28 days (C) after STZ injection. (D, E) Western-
immunoblots showing the myocardial expression of angiotensin II type 1 (AT1) receptor and p22 phox 3 days (D) and 28 days (E) after STZ
injection. GAPDH protein expression was used as control. Immunoblots are representative of three separate experiments. (F–I) Quantiﬁcation of
AT1 receptor on day-3 (F), p22 phox on day-3 (G), AT1 receptor on day-28 (H) and p22 phox on day-28 (I). Densitometric analysis of immuno-
reactive bands was performed using Scion Image software. The results are means ± S.E.M. from 3–5 experiments. Open bar, NTG; closed bar, TG.
*P < 0.05, **P < 0.01 vs. N, D + L and D + T of the same genetic group. #P < 0.05 vs. D of NTG group.
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days after STZ injection (Fig. 4E–H). Myocardial cell diame-
ter, % of ﬁbrosis and the expression of ANP, TGFb1 and col-
lagen III were signiﬁcantly elevated in TG mice relative to
NTG mice 28 days after STZ injection (Fig. 4A–H). Treatment
with either losartan or tempol signiﬁcantly attenuated the
increase in myocardial cell diameter, cardiac ﬁbrosis and
the myocardial expression of ANP, TGFb1 and collagen
III in both TG and NTG mice 28 days after STZ injection
(Fig. 4A–H). The results are means ± S.E.M. from 3–5
experiments.
3.6. Treatment with losartan or tempol attenuates MAPK
signaling in the diabetic myocardium
Previously, we showed that activation of JNK was increased
on day 3 and decreased on day 28, whereas the activation of
p38 MAPK was decreased on day 3, but increased on day 28
[15]. ERK 1/2 was not activated at either time [15]. In the pres-
ent study, we examined the eﬀect of treatment with either
losartan or tempol on the JNK (using 3-day samples) and
p38 MAPK (using 28-day samples) signaling. Our results
showed that treatment with either losartan or tempol attenu-
ated the myocardial activation of JNK and p38 MAPK at 3
days and 28 days after STZ injection, respectively, in bothTG and NTG mice (Fig. 5A–D). Data are presented as the
mean signal intensity ± S.E.M. from 3 experiments.4. Discussion
Hyperglycemia activates the local renin angiotensin system,
resulting in the formation of angiotensin II [7,8], and it has
been shown in both clinical and experimental studies that
angiotensin II induces oxidative damage by producing ROS
through the NADH/NADPH oxidase system [18]. In addition,
myocardial apoptosis has also been reported in both diabetic
patients [5] and diabetic animals [7,8]. Although, activation
of GSK3b has been shown to induce myocardial apoptosis
[2], the role of GSK3b has been in the diabetic myocardium
is largely unknown. GSK3b is normally active in the cell, but
becomes inactivated when phosphorylated at ser-9 by Akt
[3]. In addition inactivation of GSK3b is also correlated to
myocardial hypertrophy [3]. In this study, we found that the
phosphorylation of both Akt and GSK3b at ser-9 was signiﬁ-
cantly decreased 3 days after STZ injection in the myocardium
of diabetic animals compared to that in age matched normal
animals, which indicates that GSK3b activity is upregulated
in the early stage of STZ-induced diabetic myocardium relative
Fig. 2. GSK3b signaling in streptozotocin-induced myocardial apoptosis. (A) Western-immunoblots showing the myocardial expression of phospho-
Akt (p-Akt), Akt, phospho-GSK3b (p-GSK3b), GSK3b and activated caspase 3 three days after STZ injection. GAPDH protein expression was used
as control. These immunoblots are representative of three separate experiments. (For abbreviations, see legend of Fig. 1.) (B–D) Quantiﬁcation of
Akt (B) GSK3b (C) and activated caspase 3 (D) three days after STZ injection. Densitometric analysis of immuno-reactive bands was performed
using Scion Image software. (E) Myocardial tissue sections stained for TUNEL positive apoptotic nuclei (indicated by arrows) 3 days after STZ
injection. Magniﬁcation 400·. (F) Quantiﬁcation of % of TUNEL-positive apoptotic cardiac myocytes 3 days after STZ injection. The results are
means ± S.E.M. from 3–5 experiments. Open bar, NTG; closed bar, TG. *P < 0.05, **P < 0.01 vs. N, D + L and D + T of the same genetic group.
#P < 0.05 vs. D of NTG group.
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be a downstream event in GSK3b signaling in the mediation of
myocardial apoptosis [19]. In this study, we examined myocar-
dial apoptosis by assessing both caspase-3 activation and TU-
NEL staining. We found that expression of activated caspase 3
and the amount of myocardial apoptosis were signiﬁcantly in-
creased 3 days after STZ injection, and were correlated with
the enhanced activation of GSK3b. Our results suggest for
the ﬁrst time that GSK3b plays an important role in mediating
myocardial apoptosis in the diabetic myocardium. Since, insu-
lin is reported to negatively regulate GSK3b activity [1], we be-
lieve that STZ-induced lack of insulin may be one potential
event resulting in the activation of GSK3b in the early stage
of experimental diabetes in the present study. Although the
relationship between 14-3-3 protein and GSK3b in the regula-
tion of apoptosis is not well established, we hypothesize that
on day 3 the pro-apoptotic signaling (GSK3b) may exceed
the anti-apoptotic signaling (14-3-3). However, further studieswill be required to conﬁrm this. Previously, we showed that the
activation of JNK was correlated with the myocardial apopto-
sis [15]. Very recently, Enguita et al. [20] reported that JNK as
well as GSK3b signaling pathways mediate cell death path-
ways. This suggested that, it was worthwhile to examine the
roles of GSK3b and JNK with respect to 14-3-3 protein in
mediating myocardial apoptosis in the diabetic myocardium.
It is interesting to note that the phosphorylation of GSK3b
was signiﬁcantly decreased in the myocardium of DN-14-3-3
mice, compared to that of NTG mice 3 days after STZ injec-
tion, which shows that GSK3b becomes more highly activated
in DN-14-3-3 mice, in which about 50% of the function of pan-
14-3-3 protein is inhibited as we demonstrated previously [12].
Interestingly, 14-3-3 has been shown to have a signiﬁcant inter-
action with upstream eﬀectors of both GSK3b and JNK, such
as Akt [21] and apoptosis signal regulating kinase-1 [22],
respectively. Whether 14-3-3 protein prevents apoptosis in
the diabetic myocardium by direct or indirect interaction with
Fig. 3. GSK3b phosphorylation and NFATc3 nuclear translocation. (A) Western-immunoblots showing the myocardial expression of PKCb2,
phospho-Akt (p-Akt), Akt, phospho-GSK3b (p-GSK3b) and GSK3b 28 three days after STZ injection. These immunoblots are representative of
three separate experiments. (For abbreviations, see legend of Fig. 1.) (B–D) Quantiﬁcation of PKCb2 (B), Akt (C) and GSK3b (D) 28 days after STZ
injection. Densitometric analysis of immuno-reactive bands was performed using Scion Image software. (E) Myocardial tissue sections showing the
nuclear staining for NFATc3 (indicated by arrows) 28 days after STZ injection. Magniﬁcation 1000·. (F) Quantiﬁcation of the nuclear translocation
of NFATc3 in cardiac myocytes 28 days after STZ injection. The results are means ± S.E.M. from 3–5 experiments. Open bar, NTG; closed bar, TG.
*P < 0.05, **P < 0.01 vs. N, D + L and D + T of the same genetic group. #P < 0.05 vs. D of NTG group.
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answering this question will require further research.
GSK3b has been shown to inhibit cardiac hypertrophy by
preventing the nuclear translocation of NFAT3 via phosphor-
ylation of NFAT3 [23]. NFATc3 is a transcription factor
which activates several genes related to cardiac hypertrophy
[17]. Phosphorylation of NFAT facilitates the binding of 14-
3-3 protein to NFAT, and consequently NFATc3 is localized
to the cytoplasm and the NFATc3-mediated transcription is
inhibited [4]. In the present study, the phosphorylation of
GSK3b and the nuclear translocation of NFATc3 were ele-
vated in NTG mice, with a pronounced increase observed in
DN-14-3-3 mice relative to NTG mice 28 days after STZ injec-
tion, without a signiﬁcant alteration in Akt activity, suggesting
that there may be other upstream activators of GSK3b which
control its signaling in the diabetic myocardium converting the
pro-apoptotic stimuli of GSK3b observed in early stages of the
disease, and that these other activators were more active in
DN-14-3-3 mice. In this study, as reported earlier [24], cardiac
hypertrophy and its marker protein ANP, and cardiac ﬁbrosis
and its marker proteins TGFb1 and collagen III, were signiﬁ-
cantly elevated in DN-14-3-3 mice relative to NTG mice 28days after STZ injection (Fig. 4). Since NFATc3 is regulated
by both GSK3b and 14-3-3 protein, the partial inactivation
of 14-3-3 protein in DN-14-3-3 mice may have resulted in
higher nuclear translocation of NFATc3 and exacerbation of
cardiac hypertrophy in the myocardium of DN-14-3-3 mice
relative to NTG mice 28 days after STZ injection . Our results
are in accordance with the reported ﬁnding that shows the
inhibition of pan-14-3-3 protein caused the phosphorylation
and inactivation of GSK3b, which led to cardiac hypertrophy
[4]. Although cardiac hypertrophy is often associated with
ﬁbrosis, as observed in the present study, the role of GSK3b
in the induction of cardiac ﬁbrosis still remains elusive. Laviola
et al. [25] failed to observe a signiﬁcant change in GSK3b
phosphorylation after 6 weeks after of diabetes induction in
rats. Although, this discrepancy might be due to species diﬀer-
ence, it suggests that GSK3b seems to have multiple roles in
the diabetic myocardium.
Recently, GSK3b was also shown to be inactivated by
PKC [26], and several studies including the present study
indicated that the PKCb2 isoform is elevated in the diabetic
myocardium [27]. It is intriguing to note that in the present
study a parallel relationship was observed between the level
Fig. 4. Treatment with losartan and tempol attenuates STZ-induced cardiac hypertrophy and ﬁbrosis. (A) Myocardial tissue sections obtained 28
days after STZ injection and stained with hematoxylin and eosin (H-E). Magniﬁcation 400·. (B) Myocardial tissue sections obtained 28 days after
STZ injection and stained by azan-mallory (A-M) method. Blue areas indicate ﬁbrosis. Magniﬁcation 100·. (For abbreviations, see legend of Fig. 1.)
(C) Quantiﬁcation of the myocardial cell diameter using H-E stained tissue sections 28 days after STZ injection. (D) Quantiﬁcation of the % of
myocardial ﬁbrosis using A-M stained tissue sections 28 days after STZ injection. (E) Western-immunoblots showing the expression of ANP, TGFb1
and collagen III in protein lysate obtained from left ventricular tissue of transgenic TG and NTG mice 28 days after STZ injection. Equal amounts of
total protein were loaded in each lane, and GAPDH protein expression was used as control. These immunoblots are representative of three separate
experiments. (F–H) Quantiﬁcation of ANP (F), TGFb1 (G) and collagen III (H) protein expressions normalized with GAPDH. Densitometric
analysis of immuno-reactive bands was performed using Scion Image software. The results are means ± S.E.M. from 3–5 experiments. Open bar,
NTG; closed bar, TG. *P < 0.05, **P < 0.01 vs. N, D + L and D + T of the same genetic group. #P < 0.05 vs. D of NTG group.
Fig. 5. Treatment with losartan and tempol attenuates MAPK signaling in the diabetic myocardium. (A) Western-immunoblots showing the
myocardial expression of phospho-JNK (p-JNK) and JNK 3 days after STZ injection. (B) Western-immunoblots showing the myocardial expression
phospho-p38 MAPK (p-p38 MAPK) and p38 MAPK 28 days after STZ injection. These immunoblots are representative of three separate
experiments. (For abbreviations, see legend of Fig. 1.) (C) Quantiﬁcation of the activation of JNK three days after STZ injection. (D) Quantiﬁcation
of the activation of p38 MAPK 28 days after STZ injection. Densitometric analysis of immuno-reactive bands was performed using Scion Image
software, and data are represented as the mean signal intensity ± S.E.M. from three experiments. Open bar, NTG; closed bar, TG. *P < 0.05,
**P < 0.01 vs. N, D + L and D + T of the same genetic group. #P < 0.05 vs. D of NTG group.
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(an indicator of inactive GSK3b), which leads us to specu-
late that PKCb2 may negatively regulate GSK3b, resulting
in further activation of the nuclear translocation of NFATc3
and the transcription of cardiac hypertrophic genes in the
diabetic myocardium. Moreover, we showed previously that
the level of phosphorylation of p38 MAPK was signiﬁcantlyhigher 28 days after STZ injection, and furthermore, the
phosphorylation of p38 MAPK was signiﬁcantly higher in
DN-14-3-3 mice relative to NTG mice 28 days after STZ
injection [15]. Future studies addressing the relationships
among 14-3-3 protein, PKCb2, GSK3b and p38 MAPK
may provide insights into the pathogenesis of the diabetic
myocardium.
Fig. 7. An illustration of signaling pathways involved in diabetes-
induced myocardial hypertrophy and ﬁbrosis.
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ponent of the NADPH oxidase, via de novo synthesis of DAG
[28], which can further activate PKC [29]. Moreover, it has
been shown that angiotensin II-induced NADPH oxidase acti-
vation is partly mediated through PKC [29,30]. Therefore, the
possibility of indirect control of oxidative stress by GSK3b
through PKC also exists in the diabetic myocardium. In the
present study, the number of angiotensin II-positive cardio-
myocytes and the expression of AT1 receptor and p22 phox
were signiﬁcantly increased 3 and 28 days after STZ injection
in both TG and NTG mice (Fig. 1). However, the myocardial
expression of AT2 receptor did not diﬀer among the groups
(data not shown). These results show that myocardial angio-
tensin II and oxidative stress are elevated in the diabetic myo-
cardium. Also, the expression of p22 phox was signiﬁcantly
higher in TG mice on both 3 and 28 days after STZ injection
relative to that in the NTG mice at the same times. Therefore,
the enhanced expression of PKCb2 in DN-14-3-3 mice seems
to be responsible for the enhanced expression of p22 phox.
It is interesting to note that both the drugs used in the present
study have been reported to have the ability to alter blood glu-
cose levels [31,32]. In this study, however, the blood glucose le-
vel remained unaltered. One possible explanation for this might
be that streptozotocin induced the destruction of beta cells and
depleted the levels of insulin, and moreover since tempol has
been shown to improve insulin sensitivity, these drugs may
not aﬀect blood glucose per se but rather act by indirect mech-
anisms. However, this is still speculative and can only be veriﬁed
after further investigation. We observed similar improvements
after AT-1 receptor blockade as well as reduction of oxidative
stress, suggesting that these events are essential for the develop-
ment of diabetic cardiomyopathy and inhibiting any of these
causes improvement in the molecular and pathological events
in the diabetic myocardium. Tempol, a super oxide dismutase
mimetic, through blockade of AT-1 receptor and reducing angi-
otesin II levels caused a similar reduction to Losartan in active
GSK3b/JNK-induced caspase-3 signaling 3 days after STZ
injection (Fig. 6). Also, treatment with either losartan or tempol
attenuated STZ-induced cardiac hypertrophy and ﬁbrosis,
through attenuating the inactivation of GSK3b and thus pre-
venting the nuclear translocation of NFATc3, and also attenu-
ated the PKCb2 and p38 MAPK signaling 28 days after STZ
injection (Fig. 7). All the eﬀects of losartan and tempol were
mediated through attenuation of both myocardial angiotensinFig. 6. An illustration of signaling pathways involved in diabetes-
induced myocardial apoptosis.II and oxidative stress, as evidenced by the reduction in the
number of angiotensin II-positive cardiomyocytes and the
reduction of the expression of p22 phox (Fig. 1). A primary
mediator of angiotensin II stimulated collagen production
in vitro is thought to be TGFb1 [33]. In this study, treatment
with either losartan or tempol attenuated the expression of
TGFb1 and collagen III (Fig. 4). Collectively, our results sug-
gest that angiotensin II via AT1 receptor and oxidative stress
play a major role in diabetes-induced myocardial apoptosis,
hypertrophy and ﬁbrosis, and that the treatment with either
an AT1 receptor blocker or with an antioxidant will be beneﬁ-
cial for diabetic cardiomyopathy. However, further studies
are required to verify this. Moreover, based on our results we
could not diﬀerentiate between the eﬀect of treatment with
losartan and tempol. These results suggest that the relationship
among angiotensin II, oxidative stress and GSK3b should be
studied. Further studies are warranted to clarify the dual role
of GSK3b in the diabetic myocardium.
In conclusion, our results strongly suggest the role of GSK3b
signaling in the diabetic myocardium, where GSK3b is more
activated at the early stage of experimental diabetes, which at
least in part contributes to the myocardial apoptosis. More-
over, the inactivation of GSK3b and nuclear translocation of
NFATc3 probably at least in part contributes to the myocar-
dial hypertrophy and ﬁbrosis at later stages of experimental
diabetes. Inactivation of 14-3-3 protein in DN-14-3-3 mice
exacerbates cardiac apoptosis and hypertrophy, eﬀects which
are at least in part mediated through enhanced activation of
GSK3b and GSK3b phosphorylation-mediated enhanced nu-
clear translocation of NFATc3. Also, treatment with losartan
or tempol attenuates experimental diabetes-induced myocar-
dial apoptosis, hypertrophy and ﬁbrosis through attenuating
the signaling of GSK3b, p38 MAPK, JNK and PKCb2.
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